Clear Cell Renal Cell CarcinomaPhase 3NCT01198158
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy
A Phase 3 study testing Bevacizumab, Everolimus and Laboratory Biomarker Analysis in people with Clear Cell Renal Cell Carcinoma and Recurrent Renal Cell Carcinoma, run by National Cancer Institute (NCI) at 524 sites in United States.
Trial summary
This randomized phase III trial studies giving everolimus together with bevacizumab to see how well it works compared to everolimus alone in treating patients with advanced kidney cancer that progressed after first-line therapy. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7
- What is being tested?
- Bevacizumab, Everolimus and Laboratory Biomarker Analysis
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 77 participants
- Where
- 524 sitesUnited States
- Study dates
- 15 Sep 2010to 16 Dec 2017
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Renal cell carcinoma with some component of clear cell histology
- Metastatic or unresectable disease
- Must have been treated with at least 1 prior VEGFR tyrosine kinase inhibitor treatment and have progressed or have been intolerant to treatment
- No prior systemic therapy with a vascular endothelial growth factor (VEGF) binding agent (e.g., bevacizumab)
- No prior systemic therapy with any mechanistic target of rapamycin (mTOR) inhibitor (e.g., sirolimus, temsirolimus, everolimus)
- Prior cytokine therapy is allowed
Show all 46Show fewer
- Any systemic therapy must be completed at least 4 weeks prior to registration
- >= 2 weeks since any prior radiation (including palliative)
- Patients must not have had a major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks prior to study registration, and must have fully recovered from any such procedure
- The following are not considered to be major procedures: thoracentesis, paracentesis, port placement, laparoscopy, thoracoscopy, bronchoscopy, endoscopic ultrasonographic procedures, mediastinoscopy, skin biopsies, incisional biopsies and routine dental procedures
- Patients must have measurable disease by RECIST criteria; lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 2 cm with conventional techniques or as >= 1 cm with spiral computed tomography (CT) scan
- No active brain metastases: patients with treated, stable brain metastases for at least three months are eligible as long as they meet the following criteria:
- Treated brain metastases are defined as having no ongoing requirement for steroids and no evidence of progression or hemorrhage after treatment for at least 3 months, as ascertained by clinical examination and brain imaging (magnetic resonance imaging [MRI] or CT) (stable dose of anticonvulsants are allowed); treatment for brain metastases may include whole brain radiotherapy (WBRT), radiosurgery (RS; Gamma Knife, linear accelerator [LINAC], or equivalent) or a combination as deemed appropriate by the treating physician; patients with central nervous system (CNS) metastases treated by neurosurgical resection or brain biopsy performed within 3 months prior to day 1 are not eligible
- Baseline brain imaging (MRI/CT) is required
- No serious non-healing wound, ulcer, or bone fracture
- No arterial thrombotic events within 6 months of registration:
- Including transient ischemic attack (TIA), cerebrovascular accident (CVA), peripheral arterial thrombus, unstable angina or angina requiring surgical or medical intervention in the past 6 months, or myocardial infarction (MI); patients with clinically significant peripheral artery disease (i.e., claudication on less than one block), significant vascular disease (i.e., aortic aneurysm, history of aortic dissection), or any other arterial thrombotic event are ineligible
- Patients who have experienced a deep venous thrombosis or pulmonary embolus within the past 6 months must be on stable therapeutic anticoagulation to be enrolled to this study
- Patients receiving anti-platelet agents and prophylactic anticoagulation are eligible
- No inadequately controlled hypertension: (defined as a blood pressure of >= 160 mmHg systolic and/or >= 90 mmHg diastolic on medication), or any prior history of hypertensive crisis or hypertensive encephalopathy
- No known severe impairment of lung function, defined as >= grade 2 dyspnea or cough, or either:
- Requirement of supplemental oxygen, or
- In cases where pulmonary function or pulse oximetry tests have been obtained, forced expiratory volume of the lung in one second (FEV1) or forced vital capacity (FVC) are < 50% of predicted, or single breath diffusing capacity of the lung for carbon monoxide (DLCO) is < 35% of predicted or resting room oxygen saturation is less than 90%
- No active or severe liver disease (e.g. acute or chronic hepatitis, cirrhosis)
- No positive serology for anti-hemoglobin C (HBC) or anti-hepatitis C virus (HCV) antibodies; hepatitis B virus (HBV) seropositive patients (hepatitis B surface antigen [HBsAg] positive) are eligible if they are closely monitored for evidence of active HBV infection by HBV deoxryribonucleic acid (DNA) testing and agree to receive suppressive therapy with lamivudine or other HBV-suppressive therapy until at least 4 weeks after the last dose of everolimus
- No New York Heart Association (NYHA) class >= 2 congestive heart failure
- No active bleeding or chronic hemorrhagic diathesis or increased risk for bleeding: Including but not limited to history of major bleeding within 6 months (e.g. gastrointestinal, lung, CNS sites; or required transfusion support)
- No history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months prior to the initiation of treatment
- No ongoing immunosuppressive therapy: including chronic systemic treatment with corticosteroids (>= 10 mg/day prednisone equivalent)
- Archival tissue must be available for submission: though it is optional patients to choose to participate in the correlative substudies or not
- Patients who are pregnant or nursing are not eligible
- Women of child bearing potential must have a negative serum or urine pregnancy test within 16 days prior to registration
- Women of child-bearing potential include:
- Any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea >= 12 consecutive months)
- Women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level > 35m IU/mL
- Women who are using oral, implanted or injectable contraceptive hormones or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy)
- Performance status Eastern Cooperative Oncology Group (ECOG) 0-2 or Karnofsky score >= 60%
- Granulocytes >= 1,500/μL
- Platelet count >= 100,000/μL
- Calculated creatinine clearance >= 30 mL/minute (modified Cockroft and Gault formula)
- Bilirubin =< 1.5 x upper limits of normal
- Aspartate aminotransferase (AST) =< 2.5 x upper limits of normal (ULN)
- Fasting serum triglycerides =< 200 mg/dL
- Serum cholesterol =< 300 mg/dL
- Fasting serum glucose =< 1.5 x ULN
- Urine protein to creatinine ratio < 1.0 or urine protein =< 1+
Who cannot join
None listed.
Trial locations and contacts
524 sites in 1 country.
300 sites in 1 country
United States300 sites
Pali Momi Medical Center
‘Aiea, Hawaii, 96701
Abington Memorial Hospital
Abington, Pennsylvania, 19001
Bixby Medical Center
Adrian, Michigan, 49221
Hickman Cancer Center
Adrian, Michigan, 49221
Summa Akron City Hospital/Cooper Cancer Center
Akron, Ohio, 44304
Cleveland Clinic Akron General
Akron, Ohio, 44307
Phoebe Putney Memorial Hospital
Albany, Georgia, 31701
Medini, Eitan MD (UIA Investigator)
Alexandria, Minnesota, 56308
Lehigh Valley Hospital-Cedar Crest
Allentown, Pennsylvania, 18103
Kaiser Permanente-Anaheim
Anaheim, California, 92806
Langlade Hospital and Cancer Center
Antigo, Wisconsin, 54409
Kaiser Permanente-Deer Valley Medical Center
Antioch, California, 94531
Fox Valley Hematology and Oncology SC-Appleton
Appleton, Wisconsin, 54913
PCR Oncology
Arroyo Grande, California, 93420
Mission Hospital Inc-Memorial Campus
Asheville, North Carolina, 28801
Harold Alfond Center for Cancer Care
Augusta, Maine, 04330
The Medical Center of Aurora
Aurora, Colorado, 80012
Kaiser Permanente-Baldwin Park
Baldwin Park, California, 91706
Greater Baltimore Medical Center
Baltimore, Maryland, 21204
MedStar Franklin Square Medical Center/Weinberg Cancer Institute
Baltimore, Maryland, 21237
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287
Eastern Maine Medical Center
Bangor, Maine, 04401
Summa Barberton Hospital
Barberton, Ohio, 44203
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, 70809
Bronson Battle Creek
Battle Creek, Michigan, 49017
McLaren Cancer Institute-Bay City
Bay City, Michigan, 48706
Franciscan Saint Francis Health-Beech Grove
Beech Grove, Indiana, 46107
Kaiser Permanente-Bellflower
Bellflower, California, 90706
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, 94704
Central Vermont Medical Center/National Life Cancer Treatment
Berlin Corners, Vermont, 05602
Walter Reed National Military Medical Center
Bethesda, Maryland, 20889-5600
University of Iowa Healthcare Cancer Services Quad Cities
Bettendorf, Iowa, 52722
Spectrum Health Big Rapids Hospital
Big Rapids, Michigan, 49307
Billings Clinic Cancer Center
Billings, Montana, 59101
Saint Vincent Healthcare
Billings, Montana, 59101
Montana Cancer Consortium NCORP
Billings, Montana, 59102
Saint Vincent Frontier Cancer Center
Billings, Montana, 59102
Mid Dakota Clinic
Bismarck, North Dakota, 58501
Saint Alexius Medical Center
Bismarck, North Dakota, 58501
Sanford Bismarck Medical Center
Bismarck, North Dakota, 58501
Saint Joseph Medical Center
Bloomington, Illinois, 61701
Illinois CancerCare-Bloomington
Bloomington, Illinois, 61704
Saint Luke's Mountain States Tumor Institute
Boise, Idaho, 83712
Central Care Cancer Center - Bolivar
Bolivar, Missouri, 65613
Brigham and Women's Hospital
Boston, Massachusetts, 02115
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
Boulder Community Hospital
Boulder, Colorado, 80301
Toledo Clinic Cancer Centers-Bowling Green
Bowling Green, Ohio, 43402
Bozeman Deaconess Hospital
Bozeman, Montana, 59715
Cox Cancer Center Branson
Branson, Missouri, 65616
Steward Saint Elizabeth's Medical Center
Brighton, Massachusetts, 02135
Bryn Mawr Hospital
Bryn Mawr, Pennsylvania, 19010
Veterans Affairs Western New York Health Care System-Buffalo
Buffalo, New York, 14215
Mills-Peninsula Medical Center
Burlingame, California, 94010
Lahey Hospital and Medical Center
Burlington, Massachusetts, 01805
University of Vermont College of Medicine
Burlington, Vermont, 05405
Aurora Cancer Care-Southern Lakes VLCC
Burlington, Wisconsin, 53105
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
Butler Memorial Hospital
Butler, Pennsylvania, 16001
Saint James Community Hospital and Cancer Treatment Center
Butte, Montana, 59701
Cooper Hospital University Medical Center
Camden, New Jersey, 08103
Graham Hospital Association
Canton, Illinois, 61520
Illinois CancerCare-Canton
Canton, Illinois, 61520
Mercy Medical Center
Canton, Ohio, 44708
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Southeast Cancer Center
Cape Girardeau, Missouri, 63703
Illinois CancerCare-Carthage
Carthage, Illinois, 62321
Memorial Hospital
Carthage, Illinois, 62321
Rocky Mountain Oncology
Casper, Wyoming, 82609
East Bay Radiation Oncology Center
Castro Valley, California, 94546
Valley Medical Oncology Consultants-Castro Valley
Castro Valley, California, 94546
Physicians' Clinic of Iowa PC
Cedar Rapids, Iowa, 52402
Saint Luke's Hospital
Cedar Rapids, Iowa, 52402
Mercy Hospital
Cedar Rapids, Iowa, 52403
Oncology Associates at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Providence Regional Cancer System-Centralia
Centralia, Washington, 98531
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599
Roper Hospital
Charleston, South Carolina, 29401
West Virginia University Charleston Division
Charleston, West Virginia, 25304
Saint Luke's Hospital
Chesterfield, Missouri, 63017
Jesse Brown Veterans Affairs Medical Center
Chicago, Illinois, 60612
John H Stroger Jr Hospital of Cook County
Chicago, Illinois, 60612
University of Illinois
Chicago, Illinois, 60612
Presence Resurrection Medical Center
Chicago, Illinois, 60631
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637
Weiss Memorial Hospital
Chicago, Illinois, 60640
Marshfield Clinic-Chippewa Center
Chippewa Falls, Wisconsin, 54729
University of Cincinnati/Barrett Cancer Center
Cincinnati, Ohio, 45219
Clackamas Radiation Oncology Center
Clackamas, Oregon, 97015
Medical Oncology and Hematology Associates-West Des Moines
Clive, Iowa, 50325
Mercy Cancer Center-West Lakes
Clive, Iowa, 50325
North Coast Cancer Care-Clyde
Clyde, Ohio, 43410
Penrose-Saint Francis Healthcare
Colorado Springs, Colorado, 80907
University of Missouri - Ellis Fischel
Columbia, Missouri, 65212
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210
Carolinas HealthCare System NorthEast
Concord, North Carolina, 28025
Mercy Hospital
Coon Rapids, Minnesota, 55433
Geisinger Medical Center
Danville, Pennsylvania, 17822
Grandview Hospital
Dayton, Ohio, 45405
Good Samaritan Hospital - Dayton
Dayton, Ohio, 45406
Miami Valley Hospital
Dayton, Ohio, 45409
Samaritan North Health Center
Dayton, Ohio, 45415
Dayton NCI Community Oncology Research Program
Dayton, Ohio, 45420
Decatur Memorial Hospital
Decatur, Illinois, 62526
Heartland Cancer Research NCORP
Decatur, Illinois, 62526
Kaiser Permanente-Franklin
Denver, Colorado, 80205
Porter Adventist Hospital
Denver, Colorado, 80210
Presbyterian - Saint Lukes Medical Center - Health One
Denver, Colorado, 80218
SCL Health Saint Joseph Hospital
Denver, Colorado, 80218
Rose Medical Center
Denver, Colorado, 80220
Colorado Cancer Research Program NCORP
Denver, Colorado, 80222
Iowa Methodist Medical Center
Des Moines, Iowa, 50309
Iowa-Wide Oncology Research Coalition NCORP
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates-Des Moines
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates-Laurel
Des Moines, Iowa, 50314
Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
Iowa Lutheran Hospital
Des Moines, Iowa, 50316
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, 48201
Henry Ford Hospital
Detroit, Michigan, 48202
Duke University Medical Center
Durham, North Carolina, 27710
Greenville Health System Cancer Institute-Easley
Easley, South Carolina, 29640
Hematology Oncology Associates of Central New York-East Syracuse
East Syracuse, New York, 13057
Marshfield Clinic Cancer Center at Sacred Heart
Eau Claire, Wisconsin, 54701
Fairview-Southdale Hospital
Edina, Minnesota, 55435
Elkhart Clinic
Elkhart, Indiana, 46514-2098
Michiana Hematology Oncology PC-Elkhart
Elkhart, Indiana, 46514
Elkhart General Hospital
Elkhart, Indiana, 46515
Union Hospital of Cecil County
Elkton, Maryland, 21921
Hematology Oncology Center Incorporated
Elyria, Ohio, 44035
Mercy Cancer Center-Elyria
Elyria, Ohio, 44035
Bay Area Breast Surgeons Inc
Emeryville, California, 94608
Epic Care Partners in Cancer Care
Emeryville, California, 94608
Swedish Medical Center
Englewood, Colorado, 80113
Ephrata Cancer Center
Ephrata, Pennsylvania, 17522
Green Bay Oncology - Escanaba
Escanaba, Michigan, 49829
Eureka Hospital
Eureka, Illinois, 61530
Illinois CancerCare-Eureka
Eureka, Illinois, 61530
Saint Francis Hospital
Federal Way, Washington, 98003
Blanchard Valley Hospital
Findlay, Ohio, 45840
McLaren Cancer Institute-Flint
Flint, Michigan, 48532
Singh and Arora Hematology Oncology PC
Flint, Michigan, 48532
Kaiser Permanente-Fontana
Fontana, California, 92335
Poudre Valley Hospital
Fort Collins, Colorado, 80524
Holy Cross Hospital
Fort Lauderdale, Florida, 33308
Radiation Oncology Associates PC
Fort Wayne, Indiana, 46804
Fort Wayne Medical Oncology and Hematology Inc-Parkview
Fort Wayne, Indiana, 46845
Atrium Medical Center-Middletown Regional Hospital
Franklin, Ohio, 45005-1066
Aurora Cancer Care-Franklin
Franklin, Wisconsin, 53132
Fredericksburg Oncology Inc
Fredericksburg, Virginia, 22401
Kaiser Permanente-Fremont
Fremont, California, 94538
Valley Medical Oncology Consultants-Fremont
Fremont, California, 94538
Kaiser Permanente-Fresno
Fresno, California, 93720
Unity Hospital
Fridley, Minnesota, 55432
Saint Luke's Mountain States Tumor Institute - Fruitland
Fruitland, Idaho, 83619
Illinois CancerCare-Galesburg
Galesburg, Illinois, 61401
Aurora Health Care Germantown Health Center
Germantown, Wisconsin, 53022
Aurora Cancer Care-Glendale
Glendale, Wisconsin, 53212
Glens Falls Hospital
Glens Falls, New York, 12801
Wayne Memorial Hospital
Goldsboro, North Carolina, 27534
CHI Health Saint Francis
Grand Island, Nebraska, 68803
Saint Mary's Hospital and Regional Medical Center
Grand Junction, Colorado, 81501
Cancer Research Consortium of West Michigan NCORP
Grand Rapids, Michigan, 49503
Mercy Health Saint Mary's
Grand Rapids, Michigan, 49503
Spectrum Health at Butterworth Campus
Grand Rapids, Michigan, 49503
Benefis Healthcare- Sletten Cancer Institute
Great Falls, Montana, 59405
Big Sky Oncology
Great Falls, Montana, 59405
Great Falls Clinic
Great Falls, Montana, 59405
North Colorado Medical Center
Greeley, Colorado, 80631
Green Bay Oncology at Saint Vincent Hospital
Green Bay, Wisconsin, 54301-3526
Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin, 54301
Green Bay Oncology Limited at Saint Mary's Hospital
Green Bay, Wisconsin, 54303
Saint Vincent Hospital Cancer Center at Saint Mary's
Green Bay, Wisconsin, 54303
Wayne Hospital
Greenville, Ohio, 45331
Saint Francis Hospital
Greenville, South Carolina, 29601
Greenville Health System Cancer Institute-Butternut
Greenville, South Carolina, 29605
Greenville Health System Cancer Institute-Faris
Greenville, South Carolina, 29605
Greenville Memorial Hospital
Greenville, South Carolina, 29605
Greenville Health System Cancer Institute-Eastside
Greenville, South Carolina, 29615
Self Regional Healthcare
Greenwood, South Carolina, 29646
Greenville Health System Cancer Institute-Greer
Greer, South Carolina, 29650
Legacy Mount Hood Medical Center
Gresham, Oregon, 97030
Kaiser Permanente - Harbor City
Harbor City, California, 90710
Hartford Hospital
Hartford, Connecticut, 06102
Illinois CancerCare-Havana
Havana, Illinois, 62644
Mason District Hospital
Havana, Illinois, 62644
Northern Montana Hospital
Havre, Montana, 59501
Geisinger Medical Center-Cancer Center Hazleton
Hazleton, Pennsylvania, 18201
Saint Peter's Community Hospital
Helena, Montana, 59601
Margaret R Pardee Memorial Hospital
Hendersonville, North Carolina, 28791
Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania, 17033-0850
Hawaii Cancer Care Inc-POB II
Honolulu, Hawaii, 96813
Queen's Medical Center
Honolulu, Hawaii, 96813
Straub Clinic and Hospital
Honolulu, Hawaii, 96813
University of Hawaii Cancer Center
Honolulu, Hawaii, 96813
Hawaii Oncology Inc-Kuakini
Honolulu, Hawaii, 96817
The Cancer Center of Hawaii-Liliha
Honolulu, Hawaii, 96817
Kaiser Permanente Moanalua Medical Center
Honolulu, Hawaii, 96819
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii, 96826
Edwards Comprehensive Cancer Center
Huntington, West Virginia, 25701
Hutchinson Area Health Care
Hutchinson, Minnesota, 55350
Franciscan Health Indianapolis
Indianapolis, Indiana, 46237
University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, 52242
Iowa City VA Healthcare System
Iowa City, Iowa, 52246
Green Bay Oncology - Iron Mountain
Iron Mountain, Michigan, 49801
Kaiser Permanente-Irvine
Irvine, California, 92618
University of Mississippi Medical Center
Jackson, Mississippi, 39216
Capital Region Southwest Campus
Jefferson City, Missouri, 65109
Fowler Family Center for Cancer Care
Jonesboro, Arkansas, 72401
Freeman Health System
Joplin, Missouri, 64804
Mercy Hospital Joplin
Joplin, Missouri, 64804
Jupiter Medical Center
Jupiter, Florida, 33458
Castle Medical Center
Kailua, Hawaii, 96734
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
West Michigan Cancer Center
Kalamazoo, Michigan, 49007
Borgess Medical Center
Kalamazoo, Michigan, 49048
Glacier Oncology PLLC
Kalispell, Montana, 59901
Kalispell Medical Oncology
Kalispell, Montana, 59901
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Presence Saint Mary's Hospital
Kankakee, Illinois, 60901
Providence Medical Center
Kansas City, Kansas, 66112
Truman Medical Center
Kansas City, Missouri, 64108
Saint Luke's Hospital of Kansas City
Kansas City, Missouri, 64111
Saint Joseph Health Center
Kansas City, Missouri, 64114
North Kansas City Hospital
Kansas City, Missouri, 64116
Heartland Hematology and Oncology Associates Incorporated
Kansas City, Missouri, 64118
Research Medical Center
Kansas City, Missouri, 64132
CHI Health Good Samaritan
Kearney, Nebraska, 68847
Aurora Cancer Care-Kenosha South
Kenosha, Wisconsin, 53142
Kettering Medical Center
Kettering, Ohio, 45429
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois, 61443
Wellmont Holston Valley Hospital and Medical Center
Kingsport, Tennessee, 37660
Vidant Oncology-Kinston
Kinston, North Carolina, 28501
Thompson Cancer Survival Center
Knoxville, Tennessee, 37916
University of Tennessee - Knoxville
Knoxville, Tennessee, 37920
Community Howard Regional Health
Kokomo, Indiana, 46904
Gundersen Lutheran Medical Center
La Crosse, Wisconsin, 54601
AMITA Health Adventist Medical Center
La Grange, Illinois, 60525
UC San Diego Moores Cancer Center
La Jolla, California, 92093
IU Health La Porte Hospital
La Porte, Indiana, 46350
Kaiser Permanente-Rock Creek
Lafayette, Colorado, 80026
Saint Anthony Hospital
Lakewood, Colorado, 80228
Saint Clare Hospital
Lakewood, Washington, 98499
McLaren Cancer Institute-Lapeer Region
Lapeer, Michigan, 48446
University Medical Center of Southern Nevada
Las Vegas, Nevada, 89102
Nevada Cancer Research Foundation CCOP
Las Vegas, Nevada, 89106
Cancer Centers of Southwest Oklahoma Research
Lawton, Oklahoma, 73505
Saint Luke's East - Lee's Summit
Lee's Summit, Missouri, 64086
Beebe Medical Center
Lewes, Delaware, 19958
Lewistown Hospital
Lewistown, Pennsylvania, 17044
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, 40536
Liberty Radiation Oncology Center
Liberty, Missouri, 64068
Wilcox Memorial Hospital and Kauai Medical Clinic
Lihue, Hawaii, 96766
Saint Rita's Medical Center
Lima, Ohio, 45801
Lima Memorial Hospital
Lima, Ohio, 45804
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
Littleton Adventist Hospital
Littleton, Colorado, 80122
Sky Ridge Medical Center
Lone Tree, Colorado, 80124
Longmont United Hospital
Longmont, Colorado, 80501
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, 90027
Kaiser Permanente-Cadillac
Los Angeles, California, 90034
McKee Medical Center
Loveland, Colorado, 80539
Centra Lynchburg Hematology-Oncology Clinic Inc
Lynchburg, Virginia, 24501
Illinois CancerCare-Macomb
Macomb, Illinois, 61455
Mcdonough District Hospital
Macomb, Illinois, 61455
Medical Center of Central Georgia
Macon, Georgia, 31201
Holy Family Memorial Hospital
Manitowoc, Wisconsin, 54221
Minnesota Oncology Hematology PA-Maplewood
Maplewood, Minnesota, 55109
Saint John's Hospital - Healtheast
Maplewood, Minnesota, 55109
Bay Area Medical Center
Marinette, Wisconsin, 54143
Marshfield Clinic
Marshfield, Wisconsin, 54449
Contra Costa Regional Medical Center
Martinez, California, 94553-3156
Saint Luke's Hospital
Maumee, Ohio, 43537
Toledo Clinic Cancer Centers-Maumee
Maumee, Ohio, 43537
Toledo Radiation Oncology at Northwest Ohio Onocolgy Center
Maumee, Ohio, 43537
Loyola University Medical Center
Maywood, Illinois, 60153
Riddle Memorial Hospital
Media, Pennsylvania, 19063
Saint Luke's Mountain States Tumor Institute - Meridian
Meridian, Idaho, 83642
Premier Oncology Hematology Associates
Merrillville, Indiana, 46410
Mount Sinai Medical Center
Miami Beach, Florida, 33140
Orange Regional Medical Center
Middletown, New York, 10940
Aurora Saint Luke's Medical Center
Milwaukee, Wisconsin, 53215
Providence Milwaukie Hospital
Milwaukie, Oregon, 97222
Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center
Minneapolis, Minnesota, 55415
Minneapolis Veterans Medical Center
Minneapolis, Minnesota, 55417
Marshfield Clinic-Minocqua Center
Minocqua, Wisconsin, 54548
Michiana Hematology Oncology PC-Mishawaka
Mishawaka, Indiana, 46545
Saint Joseph Regional Medical Center-Mishawaka
Mishawaka, Indiana, 46545
Montana Cancer Specialists
Missoula, Montana, 59802
Saint Patrick Hospital - Community Hospital
Missoula, Montana, 59802
Memorial Medical Center
Modesto, California, 95355
Holy Family Medical Center
Monmouth, Illinois, 61462
Illinois CancerCare-Monmouth
Monmouth, Illinois, 61462
University Health-Conway
Monroe, Louisiana, 71202
Mercy Memorial Hospital
Monroe, Michigan, 48162
Toledo Clinic Cancer Centers-Monroe
Monroe, Michigan, 48162
McLaren Cancer Institute-Macomb
Mount Clemens, Michigan, 48043
Virtua Memorial
Mount Holly, New Jersey, 08060
Good Samaritan Regional Health Center
Mount Vernon, Illinois, 62864
El Camino Hospital
Mountain View, California, 94040
About this study
Official title: Randomized Phase III Trial Comparing Everolimus Versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment With Tyrosine Kinase Inhibitors
This randomized phase III trial studies giving everolimus together with bevacizumab to see how well it works compared to everolimus alone in treating patients with advanced kidney cancer that progressed after first-line therapy. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can interfere with tumor growth by blocking the ability of tumor cells to grow and spread. Everolimus and bevacizumab may also stop the growth of kidney cancer by blocking blood flow to the tumor. It is not yet known whether giving everolimus together with bevacizumab is better than everolimus alone in treating patients with advanced kidney cancer that has progressed after first-line therapy.
Read the detailed description
PRIMARY OBJECTIVES:
- To compare the overall survival of patients receiving bevacizumab plus everolimus and everolimus alone among patients with advanced renal cell carcinoma progressing after first line vascular epidermal growth factor receptor (VEGFR)-tyrosine kinase inhibitor (TKI) treatment.
SECONDARY OBJECTIVES:
- To compare the progression-free survival and proportion who experience an objective response (defined as complete clinical response [cCR] + partial response [PR]) in patients with advanced renal cell carcinoma receiving bevacizumab plus everolimus and everolimus alone.
II. To compare grade 3 or higher toxicity in patients receiving each treatment regimen.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive everolimus orally (PO) once daily (QD) on days 1-28.
ARM II: Patients receive everolimus PO QD on days 1-28 and bevacizumab intravenously (IV) over 30-90 minutes on days 1 and 15.
In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 8 weeks until disease progression and then every 6 months for up to 5.5 years.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
- Being tested
- Bevacizumab, Everolimus, Laboratory Biomarker Analysis, Pharmacological Study
- Medical subject headings
- Carcinoma, Renal Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BevacizumabBiological
Also called Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin
Given IV
EverolimusDrug
Also called 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001
Given PO
Laboratory Biomarker AnalysisOther
Correlative studies
Correlative studies
| Study group | Role | What they receive |
|---|---|---|
| Arm I (everolimus) | Active comparator | Patients receive everolimus PO QD on days 1-28. Receives: Drug: Everolimus; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study |
| Arm II (everolimus with bevacizumab) | Experimental | Patients receive everolimus PO QD on days 1-28 and bevacizumab IV over 30-90 minutes on days 1 and 15. Receives: Biological: Bevacizumab; Drug: Everolimus; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Survival (OS)
Overall survival time is defined as the time from randomization to death due to any cause. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator.
Measured: The time from date of randomization to date of death due to any cause, assessed up to 5.5 years
Secondary outcomes (3)
Progression-free Survival (PFS)
Progression free survival (PFS) is defined as the time from the date of randomization to the date of disease progression or death resulting from any cause, whichever comes first. Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator.
Measured: The time from randomization to disease progression or death from any cause, assessed up to 5.5 years
Objective Response Rate (CR + PR)
The response rate (percentage) is the percent of patients whose best response was Complete Response (CR) or Partial Response (PR) as defined by RECIST 1.1 criteria. Percentage of successes will be estimated by 100 times the number of successes divided by the total number of evaluable patients.
Measured: Up to 5.5 years
Toxicities, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0
The number of patients reporting grade 3 or higher adverse events as graded by the NCI's Common Toxicity Criteria (CTCAE) Version 4 are reported here. A complete list of all reported adverse events is reported in the Adverse Events section of this report.
Measured: Up to 30 days after completion of study treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Sep 2010 (estimated)
- Study start15 Sep 2010
- Primary completion15 Dec 2017
- Study completion16 Dec 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Clear Cell Renal Cell CarcinomaStudies of the same condition, open and under way.
- More trials run by National Cancer Institute (NCI)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 77 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Responsible party
- Sponsor
- Investigators
- George Philips, Principal investigator, Alliance for Clinical Trials in Oncology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01198158
- Sponsor's protocol ID
- NCI-2011-02603
- Other IDs
- NCI-2011-02603, CDR0000684313, CALGB 90802, CALGB-90802, U10CA180821, U10CA031946
- Status last verified
- Mar 2019
- First submitted
- 8 Sep 2010
- Last updated
- 6 Mar 2019
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 6 Mar 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized Phase III Trial Comparing Everolimus Versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment With Tyrosine Kinase Inhibitors
- ClinicalTrials.gov ID
- NCT01198158
- Acronym / sponsor ID
- NCI-2011-02603
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Terminated
- Enrolment
- 77 participants (actual)
- Lead sponsor
- National Cancer Institute (NCI)US National Institutes of Health
- Study start
- 15 Sep 2010 (actual)
- Primary completion
- 15 Dec 2017 (actual)
- Study completion
- 16 Dec 2017 (actual)
- First posted
- 9 Sep 2010 (estimated)
- Results
- Posted 6 Mar 2019
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized phase III trial studies giving everolimus together with bevacizumab to see how well it works compared to everolimus alone in treating patients with advanced kidney cancer that progressed after first-line therapy. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can interfere with tumor growth by blocking the ability of tumor cells to grow and spread. Everolimus and bevacizumab may also stop the growth of kidney cancer by blocking blood flow to the tumor. It is not yet known whether giving everolimus together with bevacizumab is better than everolimus alone in treating patients with advanced kidney cancer that has progressed after first-line therapy.
Detailed description
PRIMARY OBJECTIVES:
- To compare the overall survival of patients receiving bevacizumab plus everolimus and everolimus alone among patients with advanced renal cell carcinoma progressing after first line vascular epidermal growth factor receptor (VEGFR)-tyrosine kinase inhibitor (TKI) treatment.
SECONDARY OBJECTIVES:
- To compare the progression-free survival and proportion who experience an objective response (defined as complete clinical response [cCR] + partial response [PR]) in patients with advanced renal cell carcinoma receiving bevacizumab plus everolimus and everolimus alone.
II. To compare grade 3 or higher toxicity in patients receiving each treatment regimen.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive everolimus orally (PO) once daily (QD) on days 1-28.
ARM II: Patients receive everolimus PO QD on days 1-28 and bevacizumab intravenously (IV) over 30-90 minutes on days 1 and 15.
In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 8 weeks until disease progression and then every 6 months for up to 5.5 years.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm I (everolimus) | Active comparator | Drug: Everolimus, Other: Laboratory Biomarker Analysis, Other: Pharmacological StudyPatients receive everolimus PO QD on days 1-28. |
| Arm II (everolimus with bevacizumab) | Experimental | Biological: Bevacizumab, Drug: Everolimus, Other: Laboratory Biomarker Analysis, Other: Pharmacological StudyPatients receive everolimus PO QD on days 1-28 and bevacizumab IV over 30-90 minutes on days 1 and 15. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (46 listed)
- Renal cell carcinoma with some component of clear cell histology
- Metastatic or unresectable disease
- Must have been treated with at least 1 prior VEGFR tyrosine kinase inhibitor treatment and have progressed or have been intolerant to treatment
- No prior systemic therapy with a vascular endothelial growth factor (VEGF) binding agent (e.g., bevacizumab)
- No prior systemic therapy with any mechanistic target of rapamycin (mTOR) inhibitor (e.g., sirolimus, temsirolimus, everolimus)
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BevacizumabAlso: Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, AvastinGiven IV | Biological | Arm II (everolimus with bevacizumab) |
| EverolimusAlso: 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001Given PO | Drug | Arm I (everolimus), Arm II (everolimus with bevacizumab) |
| Laboratory Biomarker AnalysisCorrelative studies | Other | Arm I (everolimus), Arm II (everolimus with bevacizumab) |
| Pharmacological StudyCorrelative studies | Other | Arm I (everolimus), Arm II (everolimus with bevacizumab) |
Primary outcome
Overall Survival (OS)
Time frame: The time from date of randomization to date of death due to any cause, assessed up to 5.5 years
Overall survival time is defined as the time from randomization to death due to any cause. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator.
3 secondary outcomes
Progression-free Survival (PFS)
Time frame: The time from randomization to disease progression or death from any cause, assessed up to 5.5 years
Objective Response Rate (CR + PR)
Time frame: Up to 5.5 years
Toxicities, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0
Time frame: Up to 30 days after completion of study treatment
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Mar 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Clear Cell Renal Cell Carcinoma
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Active, not recruitingPhase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
Not yet recruitingPhase 2
Toripalimab and Lenvatinib With or Without SBRT Before Surgery for Non-Clear Cell Kidney Cancer
Nonmetastatic Locally Advanced Non-Clear Cell Renal Cell Carcinoma
Not yet recruitingPhase 2
Pucotenlimab, Lenvatinib, and SBRT Before Surgery for Localized Clear Cell Renal Cell Carcinoma
Localized Clear Cell Renal Cell Carcinoma
Active, not recruitingPhase 1/2
Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.
Renal Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
George Philips principal investigator
Alliance for Clinical Trials in Oncology
524 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Bevacizumab, Everolimus and Laboratory Biomarker Analysis in people with Clear Cell Renal Cell Carcinoma and Recurrent Renal Cell Carcinoma, run by National Cancer Institute (NCI) at 524 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 46 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 6 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 524 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 6 Mar 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Survival (OS) (time frame: The time from date of randomization to date of death due to any cause, assessed up to 5.5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Mar 2019.